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MicroRNAs (miRNAs) are small molecules of noncoding RNA that range 
between ~19-22 nucleotides in length.  In recent years, scientists have observed that these 
small RNA molecules exist in the extracellular environment within eukaryotic organisms.  
Furthermore, these microRNA molecules are known to associate with a family of 
proteins named Argonaute proteins.  These microRNA/Argonaute protein complexes are 
the core of a larger assembly of proteins that compose the RNA Induced Silencing 
Complex (RISC).  The RISC has exhibited the ability to inhibit the translation of, or 
cleave, its target messenger RNA (mRNA), the latter of which being exclusive only to 
Argonaute 2 protein (Ago2).  It has also been observed in the literature that these 
Argonaute/miRNA complexes often target genomic regions associated with various 
cancers in humans and, currently, more than 2000 miRNAs have been discovered and 
published in the literature. 
Current methods for analyzing miRNA expression involve total RNA extraction 
using methods such as ethanol precipitation.  However, total RNA extraction does not 
take into consideration that the major functional component of post-transcriptional 
inhibition is indeed that Argonaute protein/miRNA complex and not the miRNA alone. 
In this study, we investigate a novel method to capture and detect the active 
Ago2/miRNA (miRNP) complex and quantitate associated miRNAs by utilizing an 
  
 
 
antibody against Ago2 and subsequent application of real-time PCR to successfully 
capture the active miRNP complex and quantitate the associated miRNAs.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Statement of Problem 
 
 MicroRNAs (miRNAs) are small RNA molecules that consist of ~19-25 
nucleotides.  It has been discovered that mature miRNAs circulate in the body in complex 
with a family of proteins known as Argonaute (Ago) proteins.  This microRNA-Ago2 
complex is a major component of the RNA-induced silencing complex (RISC) and has 
exhibited the ability to silence the translation of, or cleave, target mRNA complementary 
to the sequence of miRNA.  Furthermore, the cleaving ability of RISC is specific to Ago2 
protein binding with its guide miRNA strand. 
 It is important to understand that miRNAs alone are not capable of silencing 
target genes.  It is only by incorporation into the RISC that gene silencing is possible.  
Therefore, the miRNA/Ago2 complex is the active and essential component for gene 
silencing/mRNA cleavage activity.  However, the ratio of free miRNA compared to Ago2 
associated miRNA circulating the body at a given time is uncertain.  The concentration of 
Ago2 bound miRNA circulating within the body is expected to be higher than that of free 
miRNA.
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 Current methods to analyze miRNA expression in organisms rely on total RNA 
extraction and isolation from the cellular lysate followed by either quantitative PCR or 
gel electrophoresis.  However, looking at the entire RNA profile of the organism is not 
indicative of RISC activity because it is impossible determine whether the precipitated 
miRNA was free or bound by Ago.  It is for this reason that other methods of isolating 
Ago associated miRNAs need to be investigated. 
 
Specific Aims 
 
 The specific aim of this research project is to investigate an alternative method for 
RISC isolation and quantitation of associated miRNAs.  In a prior research project, our 
group was able to develop a qualitative assay for the identification of miRNAs using 
Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) 
Spectrometry.  While this presents an effective and efficient method to determine the 
specific identity of miRNA, it is subject to the same limitations as total RNA extraction 
when the target is RISC associated miRNA.   We seek to: 
1. Investigate the use of antibodies raised against Argonaute 2 protein as a way to 
isolate Argonaute proteins in complex with miRNA. 
The function of miRNA in gene silencing is directly dependent on its partnership 
with Ago proteins.  Furthermore, the ability to cleave mRNA is exhibited only in 
association with Ago2.  Because of this, it is reasonable for us to investigate a 
method that first isolates the protein.  Our ability to quantitate the miRNA 
involved in translational inhibition is directly dependent on our ability to isolate 
  
3 
 
the Ago2 protein which binds with the miRNA.   To accomplish this, we seek to 
utilize antibodies to isolate Ago2. 
2. Capture the Ago2-miRNA complex using the specific antibodies, elute the bound 
miRNA and quantitate using qRT-PCR. 
After successful isolation of the Ago2 protein, we will apply the same principle to 
isolation of the Ago2/miRNA complex.  The binding of Ago2 with its target 
miRNA will be completed, in vitro, by a reaction between Ago2 and the miRNA 
Let-7a.  After isolating the Ago2/miRNA complex we will elute the bound 
miRNA and perform quantitation using qRT-PCR. 
 
Hypothesis 
 
 We hypothesize that given an antibody specific for Ago2, it should be possible to 
isolate the Ago2-miRNA component of the RISC and subsequently elute the miRNA for 
quantitation using real-time PCR.  This approach would allow a more accurate approach 
for assessing translational inhibition due to the Ago2-miRNA complex.   
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
 
MicroRNA 
 
 MicroRNAs are small RNA molecules consisting of anywhere from ~19-25 
nucleotides.  Post-transcriptional gene silencing, also known as RNA interference (RNAi) 
is the only known function of these small RNA molecules.  MiRNAs function by binding 
to partially complementary sequences in the 3’-untranslated region of messenger RNA 
(mRNA)
 [7]
.  Binding of these untranslated sequences either suppresses translation of, or 
causes degradation of the target mRNA. 
 The translational inhibition activity of miRNAs has made them ideal candidates 
as possible blood-based biomarkers for cancer and disease.  About 50% of all known 
human miRNA genes are located in genomic regions involved with cancers
 [1,2,20]
.  
Furthermore, some hypothesize that miRNAs are passively released from the cell during 
tissue injury, such as after a heart attack
 [2]
.  
 
MicroRNA Biogenesis 
  MiRNA biogenesis can be accomplished by either transcription of the host DNA 
or from the splicing of primary mRNA.  In the first pathway, miRNA is transcribed from 
the non-coding intergenic regions of the host DNA by RNA polymerase II into primary 
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miRNA (pri-miRNA) molecules.  These pri-miRNA molecules contain a stem and 
terminal loop structure with flanking segments
[2]
.  The pri-miRNA molecules are then 
further processed by the RNase III enzyme Drosha in complex with partner protein 
DGCR8
[2,7,17]
.  Drosha works with DGCR8 to cleave the pri-miRNA molecule into 
smaller precursor (pre-miRNA) molecules with a stem-loop hairpin structure.  These pre-
miRNAs are then exported out of the nucleus to the cytoplasm by Exportin-5
[2,7,17]
.  Upon 
entry into the cytoplasm, the pre-miRNA is cleaved by RNase III enzyme Dicer along 
with transactivator RNA-binding protein (TBRP).  This produces a 19 to 25 nucleotide 
RNA duplex containing the mature strand and its complementary strand
[2]
.  It is the 
mature strand that is bound by the Ago protein while the complementary strand is 
degraded.  The mature miRNA is the guide that leads the Ago protein to the 
complementary mRNA sequence and initiates the cleavage or silencing of the target 
mRNA.  
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Figure 1.  MiRNA Biogenesis in the Cell 
 
Source: http://en.wikipedia.org/wiki/MicroRNA 
 
 
Argonaute Proteins 
 
The Argonaute (Ago) family of proteins is a major component of the RNA-
induced silencing complex (RISC).  The Ago family is composed of four members, Ago 
1-4. Ago proteins bind together with miRNA molecules to either inhibit the translation of 
or cleave target mRNA molecules, the latter of which is specifically Ago2 associated.   
Ago proteins contain a PAZ and PIWI (P-element induced wimpy testes (PIWI), 
Argonaute and Zwille), and Mid domain
[3]
.  The PAZ and PIWI domain contain an 
oligonucleotide-binding fold that engages the 3’ end of the miRNA guide strand.  The 5’ 
end of the strand is confined within a pocket of the Mid domain
[3]
.  This confinement acts 
to envelope the miRNA, thus preventing its degradation by nucleases in the extracellular 
environment.  Also, the majority of the interactions between the Ago protein and the 
guide strand are through the RNA backbone, which explains the ability of Ago proteins 
to bind miRNAs of essentially any sequence
[3]
.  
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Figure 2.  Structure of Human Argonaute 2 Protein in Complex with miRNA-20 
 
Structure of hAgo2 in complex with miRNA-20.  Shown are the PAZ, PIWI, and Mid 
domains, as well as the N domain.  Note that miRNA is bound by the active site.  The 5’ 
end is bound to the Mid domain while the 3’ end interacts with the PAZ domain.  Source: 
Elad Elkayam, et. al, The Structure of Human Argonaute-2 in complex with miR-20a, 
Cell, 150,100-110, July 6, 2012. 
 
 
RNA-Induced Silencing Complex (RISC), Translational Inhibition, and Messenger 
RNA (mRNA) Cleavage 
 
 The RISC mediates the degradation of mRNAs that are complementary to the 
miRNA guide which is loaded into the complex.  In particular, the miRNA guide strand 
is loaded into Ago2 protein which is a major component of the RISC.  However, while 
Ago2 is the major player in the RISC other proteins have been identified as essential 
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components of RNA interference (RNAi) and the RISC, one of which is the protein 
Dicer. 
 Dicer proteins, which are ~200 kDa, contain ATPase, RNA helicase, and PAZ 
domains.  They also contain two catalytic RNase III domains and a C-terminal dsRNA 
binding domain (dsRBD)
[5]
.  The primary role of these proteins involves the processing 
of precursor miRNA (pre-miRNA) into mature miRNA by cleaving of the loop from the 
duplex hairpin structure of the precursor miRNA.  However, these enzymes also play a 
role in the downstream steps of RNAi
[5]
.  Specifically, after the precursor miRNA has 
been processed into double-stranded miRNA, a heterodimer of Dicer, Dcr-2 and R2D2, 
differentiates between the stability of the 5’ termini of the RNA duplex.  Dcr2 binds to 
the 5’ end of the RNA duplex which is thermodynamically less stable while R2D2 binds 
to the 5’ end of the more stable strand and facilitates its loading into Ago2
[5]
.  The strand 
bound by Dcr2, the least thermodynamically stable strand, is then degraded. 
 In order for the bound miRNA to be loaded into Ago2, unwinding must first 
occur.  This process requires additional proteins and ATP however the function of these 
proteins is not fully understood.  While Dicer and other protein represent the “complete 
RISC”, the minimal requirement for RISC activity is Ago2 and the miRNA guide strand. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
 Enzyme-Linked Immunosorbent Assay (ELISA) is a bioanalytical technique that 
utilizes antigen-specific antibodies to detect the presence of a specific biological antigen.  
The assay is carried out on a solid-phase surface by adsorbing either the antigen or 
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antibody to the surface, hence the term immunosorbent.  Typically, immunosorbent 
assays are performed in the wells of a polystyrene microtiter plate, however, 
immunosorbent assay applications have extended to platforms such as microarray, 
microfluidic chip technology, and magnetic beads.  ELISAs can be performed in a variety 
of configurations using either fluorescent or chemiluminescent techniques as end-point 
detection methods.  ELISAs can be competitive or non-competitive and configurations 
for the assay can be direct, indirect, or sandwich configurations. 
 In our study, we utilize the non-competitive sandwich ELISA configuration.  In 
the sandwich configuration the capture antibody is first adsorbed to the plate wells.  The 
antigen is then added to the wells and incubated in the presence of the capture antibody to 
allow binding.  Then, the detection antibody is added to the wells and allowed to bind the 
antigen.  It is essential that the two antibodies bind at different epitopes on the antigen, 
and that the epitope regions do not overlap.  Binding of the antigen by the two antibodies 
effectively completes the “sandwich”.  The method of detection at this point can be either 
direct or indirect.  Using direct detection requires that the detection antibody be 
conjugated to an enzyme such as alkaline phosphatase or horse-radish peroxidase.  
Indirect methods utilize another secondary antibody that recognizes an epitope on the 
detection antibody.  This secondary antibody is conjugated with the enzyme instead of 
the detection antibody.  The last step involves addition of a fluorescent or 
chemiluminescent substrate that reacts with the enzyme conjugate to produce a detectable 
signal.  It is also important to note that a washing step is incorporated between each step 
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in order to reduce background noise in the assay due to non-specific binding between 
reagents. 
 
Figure 3.  Sandwich Configuration for the AGO2 Capture Assay 
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Real-Time Polymerase Chain Reaction 
Real-Time Polymerase Chain Reaction (RT-PCR) is an analytical technique based 
on general PCR methodology.  The term “Real-Time” comes from the fact that the end-
point detections are carried out in real-time as the nucleic acid is amplified.  The 
technique uses sequence specific primers, along with DNA polymerase to amplify a 
target sequence of nucleic acid.  The nucleic acid of interest may be DNA or RNA, with 
the latter requiring a reverse-transcription step to convert the RNA sequence into a 
complimentary DNA (cDNA) sequence prior to performing RT-PCR. 
Detection of the amplified product can be achieved using fluorescent dyes that 
intercalate in between the grooves of DNA, such as SYBR Green, or fluorescent probes 
that are complimentary regions of the target strand.  PCR amplification is exponential; 
therefore, detection plots exhibit an exponential curve.  This allows RT-PCR to be 
quantitative when comparing the plot an unknown quantity of nucleic acid to that of a 
known quantity or control. 
RT-PCR techniques have been helpful in evaluating the level of gene expression 
in cells.  For our purposes, it presents a suitable method for quantitation of miRNA 
associated with Ago2.  As has been previously stated, gene silencing via translational 
inhibition is RISC dependent.  With Ago2 being the major component of the RISC, gene 
regulation via translational inhibition can be evaluated by quantitating the amount of 
Ago2 bound miRNA using RT-PCR.  Determining the amount of silencing activity and 
target gene region can give a lot of insight into the epigenetics of post-transcriptional 
gene silencing. 
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Figure 4.  Flow Diagram of Reverse Transcription and Real-Time PCR using the 
Qiagen miScript Real-Time PCR Kit. 
 
 
Source: Qiagen miScript User Handbook  
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MicroRNA and Gene Therapy 
 It has been observed that miRNAs play a role in several biological processes such 
as development, differentiation, apoptosis, and proliferation
[2]
.  Furthermore, it has been 
observed that almost 50% of genes targeted by miRNA are located in genomic regions 
associated with cancers.  Many of the genomic targets of miRNA are involved in tumor 
initiation and progression indicating that miRNAs may possess oncogenic or tumor-
suppressive activities
[2]
. 
 It is has been proposed that miRNAs could be released within small exosomes 
into the peripheral blood during tissue injury, such as during a heart-attack, and therefore 
may also be released during cell lysis due to rapid cell growth during tumor metastasis
[2]
.  
Therefore, the expression of miRNA in the blood could serve as potential biomarkers for 
cancers.  With the number of oncogenic genomic targets associated with miRNAs, the 
therapeutic factor of miRNAs is one of great interest in the treatment of cancers and 
genetic disease. 
 The ability of miRNA to bind its target mRNA without being fully complimentary 
to the target allows miRNA to bind numerous target mRNAs.  Therefore, one miRNA 
could potentially inhibit many target genes at once and subsequently suppressing several 
genetic pathways in the process. 
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CHAPTER III 
 
CAPTURE AND DETECTION OF AGO2 USING A SPECIFIC ANTIBODY FOR  
RECOMBINANT HUMAN ARGONAUTE 2 PROTEIN 
 
 
Introduction 
 Our efforts to capture the miRNA-Ago2 complex target the Ago2 component of 
the complex.  An ELISA is ideally suited to accomplish this task.  However, an ELISA 
depends on the harmonious gelling of several factors such as configuration, antigen, 
antibody affinity and epitope binding, antibodies that can work as a matched pair, 
reduction of non-specific binding, reagent concentrations, and method of end-point 
detection.  With so many factors involved, it is necessary to determine the optimal 
parameters at necessary to detect Ago2. 
 
Materials and Methods 
 Recombinant human Argonaute 2 protein was purchased from Sino Biological.  
Mouse anti-human Ago2 monoclonal and rabbit anti-human Ago2 polyclonal antibodies 
were purchased from Abova.  An anti-rabbit alkaline phosphatase conjugated antibody 
was purchased from Jackson ImmunoResearch.  AttoPhos fluorescent substrate was 
purchased from Promega.  Tris-buffered saline with 0.2% Tween was purchased from 
Sigma Aldrich.  Costar 96 well flat bottom polystyrene plates were used for the assay. 
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Figure 5.  Results from Sino Biological’s In Vitro RISC Assay with Recombinant 
Ago2 Protein. 
 
 
 
Credit: Sino Biological;  Ago2 is enzymatically active in our conditions. The activity is 
guide RNA (let-7a) specific. The shown conditions are the rate limiting conditions (the 
cleavage activity increases significantly when reactions are incubated at 37C). 20ng per 
reaction seems to be already enough to saturate the cleavage activity in our experimental 
system. Ago2 (Cat.nr. 11079-H07B) was dissolved in H20 to concentration of 100ng/ul. 
Protein was stored at 4C and was still active after 2 weeks kept at 4C.  
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Evaluation of the AttoPhos Fluorescent Substrate 
The fluorescent limit of detection (LOD) for using the PolarSTAR Optima plate 
reader was determined.  Serial dilutions of the alkaline phosphatase conjugated anti-
rabbit secondary antibody were performed.  The dilution range for the conjugated 
antibody was from 0.6 µg/mL to 1.17 pg/mL for a total of 14 samples. 
To the wells of a microtiter plate 2 µL of each sample was pipetted in triplicate.  
25 µL of the 1 mM AttoPhos substrate was then added to each sample well and the plate 
was incubated in the dark, while shaking, for 15 minutes.  The fluorescence of each 
sample was then measured using the Optima FLUORstar fluorometer.  The incubation 
was repeated for 15 and 30 minutes respectively and re-measured.  The gain for the 
measurement was adjusted from the three blank wells which contained only 25 µL of 1X 
PBS.  
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Figure 6.  Limit of Detection for AttoPhos Fluorescent Substrate 
 
 
 From the data, the limit of detection for the AttoPhos fluorescent substrate was 
determined to be 1.2 x 10
-4
 pg/mL with the linear dynamic range falling between 1.2 x 
10
-4
 pg/mL and 6.0 x 10
-5
 pg/mL. 
 
Evaluation of the Blocking Solution 
 Following adsorption of the antibody to the microtiter plate wells, it is necessary 
to block the remaining spaces on the well surface, where no antibody adsorption 
occurred, in order to prevent nonspecific binding of a reagent following its addition to the 
wells.  Nonspecific binding of reagents to the well surface would result in inaccuracies, 
when detecting Ago2, which could result in misinterpretations of the data.  To alleviate 
this problem a blocking solution containing a protein, such as bovine serum albumin 
(BSA), is used to fill the empty spaces remaining on the bottom surface of the well.  The 
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blocking protein adsorbs to the remaining spaces on the well’s surface, and has no 
specificity toward the antibodies being used in the assay.  While the antibodies are not 
specific for the blocking proteins, high concentrations of blocking protein may potentially 
for a monolayer over the antibodies which have already been adsorbed to the well 
surface, effectively blocking the available binding sites.  Therefore, it is necessary to 
optimize the blocking process by determining the efficiency of the blocking solution at 
lower concentrations. 
We decided to determine the blocking efficiency at 1, 2, and 5 percent blocking 
solution.  The 1 and 2 percent concentrations were prepared from dilutions of the initial 
5% stock concentration.  50µL of 1, 2, and 5% blocking solution were added to the plate 
wells, in triplicate, and incubated for one hour at room temperature to allow sufficient 
adsorption.  Following incubation, the plate was washed 4X with TBST to remove any 
excess blocking solution.  50 µL of secondary antibody, conjugated with alkaline 
phosphatase, diluted 5000X (from a stock concentration of 0.6 mg/mL) in 1, 2, and 5% 
blocking buffer respectively was added to the wells corresponding the blocking 
percentages of the diluent. 
The plate was incubated at room temperature for one hour while shaking.  The 
plate was then washed 3X with TBST to remove any excess.  50 µL of 1 mM AttoPhos 
fluorescent substrate was added to each well and incubated in the dark for 15 minutes 
while shaking.  The fluorescence from each sample was measured using the POLARstar 
Optima plate reader. 
  
19 
 
Figure 7.  Evaluation of Blocking Efficiency at Varying Percentages of Blocking 
Solution 
 
 
 
 
 
 After plotting the data, it was observed that the reduction of non-specific binding 
by each percentage was comparably equal.  Using this observation, it was determined that 
the best percentage for our use was one percent.  The logic behind this was due to several 
considerations.  The first being using a lower percentage of blocking solution in the assay 
allows faster diffusion to the unoccupied spaces.  Also, less blocking protein in the 
blocking solution would lower the possibility of monolayer formation.  Monolayer 
formation of the blocking protein would potential cover the capture antibody thereby 
inhibiting binding of the antibody to its target antigen, Ago2.  
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Evaluation of Incubation Times and Concentrations for Anti-hAGO2 Rabbit 
Polyclonal and Anti-Rabbit Secondary Antibodies 
 
The incubation time necessary for optimal binding between the rabbit anti-
hAGO2 polyclonal antibody and the anti-rabbit secondary antibody was determined.  50 
µL of the anti-hAGO2 polyclonal antibody was added to 24 wells of two microtiter 
plates, at a concentration of 62.5 ng/mL, and as a negative control 1X PBS was added to 
the negative wells.  The plates were incubated overnight at room temperature to allow 
antibody adsorption. 
The plates were then washed two times with 1X TBST and blotted on a paper 
towel to remove excess liquid.  200 µL of blocking solution (1% non-fat dry milk in 
PBS) was added to the wells and incubated for one hour at room temperature.  The plates 
were then washed three times with 1X TBST and blotted on a paper towel to remove 
excess liquid. 
The anti-rabbit secondary antibody was then added to the wells, in triplicate, at 
concentrations of 1.2 µg/mL, 120 ng/mL, and 12 ng/mL.  The first plate was then 
incubated for one hour while shaking.  The other plate was incubated for two hours while 
shaking.  After each incubation, the plate was washed five times with 1X TBST and 
blotted on a paper towel to remove excess liquid.  50 µL of 1 mM AttoPhos fluorescent 
substrate was added to the wells and incubated in the dark, while shaking, for 15 minutes.  
The fluorescence was then measured using the POLARstar Optima plate reader.  
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Figure 8.  Plotted Data from the Evaluation of the Anti-Rabbit Secondary Antibody 
 
 
A.  
B.  
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A plot of the data suggests that a 5000X dilution (120 ng/mL) of the secondary 
antibody was sufficient enough to produce a strong detectable signal.  This was also in 
compliance with the suggested dilution factor from the manufacturer. 
 
Detection of Recombinant Human Ago2 Protein Using Sandwich ELISA 
 
 The complete sandwich assay was performed to determine whether the 
recombinant human Ago2 protein could be detected using the antibodies we acquired.  50 
µL of the mouse monoclonal antibody was added to 18 wells of a polystyrene microtiter 
plate and allowed to adsorb by incubating overnight at room temperature.  Following the 
incubation, the plate was washed two times with 1X TBST and blotted on a paper towel 
to remove excess liquid.  To the sample wells, 300 µL of 1% blocking solution was 
added to the wells and allowed to incubate for one hour at room temperature.  Following 
the incubation, the plate was washed two times with 1X TBST and blotted on a paper 
towel to remove excess liquid. 
To nine of the plate wells, 50 µL of recombinant Ago2 protein was added at a 
concentration of 2 µg/mL using 1% blocking solution as the diluent.  To the remaining 
nine wells, 50 µL of 1X PBS was added as a negative control.  The plate was sealed and 
incubated for one hour while shaking.  Following the incubation, the plate was washed 
three times with 1X TBST and blotted on a paper towel to remove excess liquid. 
To the first 6 wells (3 negatives, 3 samples) 50 µL of rabbit anti-human Ago2 
polyclonal antibody was added at a concentration of 2.5 µg/mL using 1% blocking 
solution as the diluent.   To the following 6 wells, polyclonal antibody was added at a 
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concentration of 250 ng/mL, and the remaining 6 wells at a concentration of 25 ng/mL.  
The plate was then sealed and incubated for one hour while shaking.  Following the 
incubation, the plate was washed three times with 1X TBST and blotted on a paper towel 
to remove excess liquid. 
To all wells, 50 µL of the anti-rabbit alkaline phosphatase conjugated secondary 
antibody was added at a concentration of 120 ng/mL.  The plate was sealed and incubated 
for one hour while shaking.  Following the incubation, the wells were washed five times 
with 1X TBST and blotted on a paper towel to remove excess liquid. 
To all wells, 50 µL of 1 mM AttoPhos fluorescent substrate was added.  The plate 
was sealed and incubated for 15 minutes in the dark while shaking.  Following the 
incubation, the fluorescence was measured using the POLARstar Optima plate reader.  
The experiment was then repeated following the exact steps while using carbonate buffer 
as the coating buffer.  The data from each experiment is below. 
  
  
24 
 
Figure 9.  Detection of Recombinant Human Argonaute 2 Protein using Sandwich 
ELISA 
 
 
A.  
 
 
B.  
  
The data plot suggests that recombinant Ago2 protein is slightly detectable as 
antibody concentrations increase.  However, the signal to noise ratio could be improved.  
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The data suggests a low binding affinity by the selected antibodies and an assay that will 
require further optimization.  The second data plot represents the repeated experiment 
using carbonate buffer as the coating buffer.  The graph suggests that detectability of 
human Ago2 is lower when using carbonate buffer most likely due to decreased antibody 
adsorption in the buffer conditions.  Therefore, we decided that using 1X PBS as the 
coating buffer would be our choice buffer moving forward. 
 
Evaluation of Diluents 
 
 Due to the low binding affinity of the antibodies, we looked at the options of 
using 1X PBS vs 1% blocking solutions as diluents.  The option to use 1X PBS as a 
diluent for during certain binding steps in the assay could possibly help improve binding 
between antibody and antigen but it comes at the risk of increased non-specific binding 
throughout the assay which would lead to higher background noise. 
 To determine the efficiency of the diluents, 8 wells of a polystyrene microtiter 
plate were blocked by adding 200 µL of 1% blocking solution and allowing to incubate 
for one hour at room temperature.  Following the incubation, the wells were washed with 
1X TBST and blotted on a paper towel to remove excess liquid.  The first four wells 
received diluents only with two receiving 50 µL of 1X PBS and the other two receiving 
50 µL of 1% blocking solution.  To the remaining four wells, 50 µL of the rabbit anti-
Ago2 polyclonal antibody was added to each well at a concentration of 2.5 µg/mL, with 
the diluent for two of the wells being 1X PBS and the diluent for the other two being 1% 
blocking solution.  The plate was sealed and allowed to incubate for one hour while 
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shaking.  Following the incubation, the wells were washed three times with 1X TBST and 
blotted on a paper towel to remove excess liquid. 
 To the 8 wells, 50 µL of the anti-rabbit alkaline phosphatase conjugated 
secondary antibody was added.  For four of the wells the diluent for the secondary 
antibody was 1X TBS.  For the remaining four, the diluent was 1% blocking solution.  
The reasoning behind the change in diluent for the alkaline phosphatase was due to 
observations in the literature that suggested that PBS diluents can inhibit the enzyme 
activity of alkaline phosphatases.  To insure that this was not the case, TBS was used as a 
diluent along with the 1% blocking solution which contains PBS.  The plate was sealed 
and allowed to incubate for one hour while shaking.  Following the incubation the wells 
were washed five times with 1X TBST and blotted on a paper towel to remove excess 
liquid. 
 Following the incubation, 50 µL of 1 mM AttoPhos Substrate was added to the 
wells and allowed to incubate for 15 minutes in the dark while shaking.  The fluorescence 
was then measured using the POLARstar Optima plate reader. 
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Figure 10.  Evaluation of Diluents 
 
 
 
 
The above graph shows the efficiency of each diluent during various steps of the 
assay.  As expected, using diluents that contained no blocking proteins resulted in higher 
levels of non-specific binding due to diffusion of blocking protein off the well surface.  
Therefore, while there is the possibility of increased antigen binding in using 1X PBS as 
a diluent, the increased background noise would negate any increased detectability do to 
non-specific binding and possibly result in false positives. 
 In analyzing the data from the graph, it would appear that the most favorable use 
of diluents with respect to lowest background noise is using the 1% blocking solution.  
Also, while there seems to be increased signal when using TBS as the diluent for the 
secondary antibody, the increase in signal is most likely due to non-specific binding by 
the secondary antibody and not lack of inhibition by PBS. 
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Results of Study 
 In the RNA-induced silencing complex, the Ago2-miRNA complex is a major 
component and plays a critical role with regard to translational inhibition and mRNA 
cleavage.  Our initial approach has been to utilize the bioanalytical technique of ELISA 
as a method to capture and detect the Ago2 component on a solid phase.  After several 
modifications to the assay parameters, we were able to successfully obtain a signal from 
the detection of Ago2 protein but further optimization is still required. 
However, our ability to quantitate Ago2 bound miRNAs does not strictly depend 
on the sensitivity of the capture assay and can simply rely on specificity and sensitivity of 
the PCR itself.  For quantitative PCR analysis of the bound miRNA, we need only a 
relatively small amount of the bound miRNA.  Therefore, a small amount of the captured 
miRNA-Ago2 complex should be more than enough to proceed with detection of the 
Ago2 associated miRNA by qRT-PCR. 
We have determined that ELISA is a practical method to capture and detect Ago2 
component of the miRNA-Ago2 complex.  We now seek to utilize this technique to 
successfully immobilize the miRNA-Ago2 complex from a sample.  The binding reaction 
between Ago2 and miRNA has been reported in the literature and can easily be 
accomplished in vitro.  Our biggest challenge may be posed by the possible affect that 
conformational change upon binding of the target miRNA could have on the binding 
affinity of the antibody.  However, given an antibody with a greater binding affinity for 
human Ago2 protein, there is great potential in the capabilities of using ELISA in tandem 
with real-time PCR to detect and quantitate Ago2 associated miRNAs.
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CHAPTER IV 
 
ASSAY DEVELOPMENT FOR DETECTION OF AGO2 ASSOCIATED MICRO-
RNAs BY REAL-TIME PCR 
 
 
Introduction 
 
 The cleaving of mRNA by the RISC is specific only to Ago2 protein once it has 
bound a miRNA guide strand.  This characteristic ability of Ago2 led us to investigate a 
method to detect Ago2 associated miRNAs.  We first sought to capture the Ago2 
component using an antibody specific for Ago2.  What follows details a practical method 
for detecting Ago2 bound miRNA. 
Coupling the immunoassay technique of ELISA with quantitative real-time PCR 
could serve as a novel high-throughput method for detecting Ago2 associated miRNAs.  
We decided to use a polyclonal antibody specific for human Ago2, adsorbed on a well 
surface, as a way to capture Ago2.  As was previously observed, the binding affinity of 
this particular antibody for Ago2 was weaker than expected using the ELISA “sandwich” 
configuration.  However, we hypothesize that the polyclonal antibody would offer a 
greater probability of capture due to the antibody being specific for several epitopes on 
Ago2.
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There are already several protocols published in the literature that detail the steps 
for in vitro formation of the miRNA-Ago2 complex.  We decided to follow a protocol 
which was published by the vendor from which we acquired the recombinant human 
Ago2 protein.  While formation of the miRNA-Ago2 complex has been accomplished, no 
other group has published work involving the capture of the miRNA-Ago2 complex 
using a solid phase ELISA.  It must also be noted that while the polyclonal antibody may 
present a greater chance of capturing the complex, the low binding affinity may be 
lowered once the Ago2 has bound to its miRNA guide strand, due to conformational 
changes that occur upon binding. 
 
Figure 11.  Flow Diagram for miRNA Detection Assay 
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Background Due to Non-Specific Binding by miRNA Let-7a 
 PCR is a technique that has the capability to detect nucleic acid down to the level 
of one copy.  This is due to the ability of PCR to amplify nuclei acid exponentially.  
Because of the sensitivity of PCR, it was important that our first step was to determine 
the affinity of our miRNA for the polyclonal antibody which is being used to immobilize 
miRNA-Ago2 complex.  MiRNA with a non-specific affinity for the antibody could 
result in skewed results and errors in quantitation. 
 In order to determine the affinity of Let-7a for the polyclonal antibody, a well of a 
polystyrene plate was coated with 50 µL of the polyclonal antibody at a concentration of 
2.5 µg/mL.  Another well served as a negative control and was not coated with the 
antibody, but rather 1X PBS only.  The wells were left to incubate overnight at room 
temperature to allow adsorption of the antibody.  Following the incubation, the wells 
were washed two times with 1X TBST and blotted on a paper towel to remove excess 
liquid.  100 µL of 1% blocking solution was then added to the wells and allowed to 
incubate for one hour at room temperature.  Following the incubation, the plate was then 
washed three times with 1X TBST and blotted on a paper towel to remove excess liquid. 
 Two each well, 50 µL of miRNA Let-7a complex mixture without the Ago2 
protein was added to each well.  The complex reaction mixture was made up in a 
microfuge tube by adding 2 µL of Let-7a at a concentration of 3.2 µM in 1X PBS, TM 
buffer (40 U/mL RNasin, 25 mM MgCl2, 1 M KCl, 16.7 mM DTT), with 1X PBS to a 
volume of 50 µL.  The plate was sealed and incubated for one hour while shaking.  
Following the incubation, the plate was washed five times with 1X TBST and blotted on 
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a paper towel to remove excess liquid.  To each well, 50 µL of Tris-EDTA buffer, with 
RNasin was added to the wells.  The plate was sealed and incubated at 65 °C for 15 
minutes.  The sample was then transferred from each well to clean RNase free microfuge 
tubes. 
 Reverse transcription was then performed on the samples using the Qiagen 
miScript Reverse Transcription (RT) kit.  2 µL of each sample was used for the reverse 
transcription reactions and the total volume was 20 µL.  Following reverse transcription 
reaction, the RT sample was diluted according to the suggested kit protocol.  The sample 
was then used for real-time PCR using the Qiagen miScript SYBR Green PCR kit. 
For the PCR reaction, 2 µL of the cDNA was used per 20 µL reaction.  The forward 
primer for the reaction was designed by Qiagen Geneglobe using the mature Let-7a 
sequence 5`-p-UGAGGUAGUAGGUUGUAUAGUU-3’.  Activation of the HotStarTaq 
DNA polymerase was achieved by an initial incubation at 95 °C for a time of 15 minutes.  
Denaturation was achieved by incubating at 94 °C for 15 seconds.  Annealing was 
achieved by incubating at 55 °C for 30 seconds and extension was accomplished by 
incubation at 70 °C for 30 seconds.  The cycle was repeated for a total of 40 PCR cycles.  
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Figure 12.  Background PCR Noise Due to Non-Specific Binding by miRNA Let-7a 
 
 
 
The data revealed a background that was higher than expected for the assay.  It 
would appear that the non-specific binding between miRNA Let-7a with the rabbit anti-
Ago2 polyclonal antibody was rather significant when comparing the two amplification 
plots.  Having such a high background due to PCR amplification of the non-specifically 
bound miRNA poses an issue for the detectability of Ago2 associated Let-7a. 
 In order to address the high background, we took into consideration the 
introduction of an exoribonuclease as a way to digest all unbound miRNA in the complex 
reaction prior to adding the reaction mix to the coated microtiter wells.  
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Reduction of Background Noise Using Exoribonuclease XRN-1 
 
We acquired an exoribonuclease, XRN-1, from New England Biolabs with the 
intention of using it to digest the excess miRNA present in the Ago2/Let-7a complex 
reaction.  The hypothesis was that digesting the excess miRNA would reduce the PCR 
background significantly enough to make the Ago2 associated miRNA amplification plot 
distinguishable.  Our first step was to determine the necessary amount of XRN-1 needed 
to digest the amount of excess Let-7a in the Ago2/Let-7a complex reaction. 
 XRN-1 is an exoribonuclease that specifically recognizes the 5’ phosphate group 
of RNA.  We wanted an exoribonuclease that specifically targeted the 5’ phosphate group 
because the 5’ phosphate is engaged by the Mid domain of the Ago2 protein and, thereby, 
protected from degradation by XRN-1.  Therefore, Let-7a miRNA that is not bound by 
Ago2 would be degraded by XRN-1.  Also, any accessible 3’ end nucleotides of the 
Ago2 bound miRNA would not be susceptible to degradation by XRN-1. In order to 
determine the amount of XRN-1 necessary to digest the amount of XRN-1 we performed 
a titration with the XRN-1 and the amount of miRNA present in the Ago2/Let-7a 
complex reaction. 
 We numbered seven microfuge tubes.  A master mix was made up for the 
Ago2/Let-7a complex reaction; 11 µL of 800 nM Ago2, 41.25 µL of TM buffer, 11 µL of 
3.2 µM phosphorylated Let-7a miRNA, and 46.75 µL of deionized water.  To tubes 2-6, 
20 µL of the Ago2/Let-7a complex master mix was added.  To tube one, only one fourth 
of the amount of miRNA, 0.8 µM, was added and the volume was adjusted to 20 µL with 
deionized water.  To tube seven the full amount of miRNA in the complex reaction, 3.2 
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µM, was added and the volume was adjusted to 20 µL with deionized water.  Neither 
tubes one or seven received XRN-1.   These tubes served as positive controls with tube 
one representing the amount of miRNA that should remain if only Ago2 bound miRNA 
remained, and tube seven representing the full amount of miRNA in the reaction.  The 
one fourth amount was determined from the ratio of Ago2 to Let-7a in the reaction 
because that was the amount of Let-7a used in the reaction is four times the amount of 
Ago2 in order to facilitate incorporation of Let-7a into every Ago2 protein. 
 To tubes two through six, 0.01, 0.1, 1, and 2U (U = 1 µL) of XRN-1 was added 
respectively in that order to each reaction tube.  Each tube was vortexed gently and 
briefly centrifuged.  The tubes were then incubated at 30 °C for 15 minutes followed by a 
10 minute incubation at 70 °C to deactivate the XRN-1.  Following the incubation, 2 µL 
of each sample was used in seven reverse transcription reactions using the Qiagen 
miScript reverse transcription kit.  Following the reverse transcription reaction, real-time 
PCR was performed using the Qiagen miScript Real-Time PCR kit with SYBR Green.  
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Figure 13.  Data from XRN-1 Titration 
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 The results of the titration experiment were rather surprising yet not 
unexplainable.  From the amplification plot, you will observe that there was little to no 
digestion of miRNA Let-7a by XRN-1 and that the levels are essentially the same.  The 
conditions of the Ago2/Let-7a complex reaction are not the optimal conditions by which 
the XRN-1 operates.  Also, the free ATP that is present in the reaction mix for the 
Ago2/Let-7a complex may be acting to quench the activity of the exoribonuclease which 
specifically targets the 5’ phosphate of ribonucleic acids.  This is a detail that we 
overlooked in utilizing this exoribonuclease.  Also, the optimal temperature for XRN-1 is 
37 °C while the optimal temperature for the Ago2/Let-7a complex formation is 30 °C.  In 
order to maintain the integrity of the protein-miRNA complex we decided to carry out the 
titration at 30 °C. 
 
XRN-1 Time Study 
 
 Following the past titration experiment two problems were noted.  The ability of 
the XRN-1 to digest Let-7a was inhibited by the presence of ATP.  And, the efficiency of 
XRN-1 was reduced when the digestion was carried out at 30 °C.  To alleviate the 
inhibition of miRNA digestion, ATP was excluded from the TM buffer.  Also, the 
reaction was again carried out at 30 °C. 
 To further optimize the conditions of digestion, a time study was performed.  In a 
microfuge tube, a master mix containing all the components of the Ago2/Let-7a reaction 
without Ago2 protein or ATP for a total volume of 20 µL.  To the tube, 1 µL of 0.5 U 
XRN-1 was added and the tube was allowed to incubate at 30 °C.  At the time points of 
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15, 30, 45, and 1 hour, 5 µL aliquots were taken from the reaction tube using a 
micropipette and transferred to a clean microfuge tube.  The aliquot was then incubated at 
70 °C to deactivate the XRN-1.  The four samples corresponding to the four time points 
were then used for the reverse transcription reactions.  For each reaction, 2 µL of each 
sample was used.  Following reverse transcription, the sample was diluted according to 
the Qiagen miScript RT kit protocol and used in the real-time PCR reaction using the 
Qiagen miScript SYBR Green PCR kit. 
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Figure 14.  XRN-1 Time Study at 30 °C 
 
Legend 
Red – Negative Control 
Green – Positive Control (1.6 uM Let-7a, no XRN-1) 
Blue – 1.6 uM Let-7a, 5U XRN-1, 15 minute incubation, 30ºC 
Yellow – 1.6 uM Let-7a, 5U XRN-1, 30 minute incubation, 30ºC 
Magenta – 1.6 uM Let-7a, 5U XRN-1, 1 hour incubation, 30ºC 
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 The results from the XRN-1 time study indicated a less than optimal conditions 
for maximum nuclease activity.  After fifteen minutes, the activity seemed to decline and 
indicated that the XRN-1 was no longer functional and was therefore dead.  For the time 
study, the free ATP had been removed from the reaction mixture eliminating the 
possibility of quenching due to the presence of free ATP.  I was then decided that, at 30 
°C, the efficiency of the XRN-1 was limited or the enzyme had died. 
 We determined that there was a possibility that at 30 °C the XRN-1 may not have 
sufficient energy to properly digest miRNA Let-7a due to the secondary structures of the 
miRNA being able to inhibit complete digestion of the miRNA.  Incompletely digested 
Let-7a molecules would still be able to be reverse-transcribed, amplified, and detected via 
real-time PCR.  In order to determine the prospective of this hypothesis we decided to 
briefly look at the possible secondary structures of Let-7a and the binding energy 
associated with each structure. 
 There are many software programs that have been developed to determine the 
secondary structures of nucleic acids, their probability of formation, and the binding 
energies between each structure.  Secondary structures of single stranded nucleic acids 
include homo dimers, heterodimers, twists and loops.  Depending on the number of bases 
involved in hydrogen bonding within, or between, the nucleic acid molecules the amount 
of energy required to break these hydrogen bonds varies.  Therefore, at lower 
temperatures, digestion of the miRNA by XRN-1 may be incomplete.  With this 
understanding, the XRN-1 time study was repeated using the same protocol and 
parameters with the incubation temperature at 37 °C.
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Figure 15.  Homo Dimer Structures and ΔG for Human miRNA Let-7a 
 
Data generated using Integrated DNA Technologies OligoAnalyzer 3.1 Software 
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Figure 16.  Secondary Structures and ΔG for Human Let-7a miRNA 
 
Data generated using Integrated DNA Technologies OligoAnalyzer 3.1 Software 
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Figure 17.  XRN-1 Time Study at 37 °C 
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 The PCR data from the time study still indicates incomplete digestion by XRN-1 
and lose of full enzymatic activity after fifteen minutes.  While more digestion was 
observed at a temperature of 37 °C, the efficiency was still low and activity seemed to 
halt.  The conditions for the complex seem to be incompatible with the conditions XRN-1 
needs to be fully efficient at cutting the excess miRNA.  Nevertheless, the conditions 
necessary to form the Ago2/Let-7a complex must not be altered.  We would continue to 
utilize the XRN-1 as a means to lower the background for the PCR detection but 
understand that, due to the reduced activity of the XRN-1, the background may only be 
slightly lowered. 
 
Detection of AGO2 Associated Let-7a Using Antibody Capture and Real-Time PCR 
 We are now ready to proceed with the detection of Ago2 associated miRNAs by 
combining ELISA based capture with quantitative real-time PCR.  Using the rabbit anti-
human Ago2 polyclonal antibody to pull down the Ago2 protein, bound to miRNA Let-
7a, and later detecting the Let-7a we hope to distinguish Let-7a bound by Ago2 from free 
Let-7a.  We hypothesize that Ago2 bound Let-7a would produce a shift left in the 
amplification plot away from the background signal for the assay.  This shift would 
indicate a greater presence of miRNA due to its binding with the Ago2 that was pulled 
down onto the solid phase by the Ago2 specific antibodies. 
 First, 50 µL of the rabbit anti-hAgo2 polyclonal antibody was added to the wells 
of a polystyrene microtiter plate and incubated overnight at room temperature to allow 
antibody adsorption.  Following the incubation, the wells were washed two times with 1X 
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TBST and blotted on a paper towel to remove excess liquid.  To the wells, 200 µL of 1% 
blocking solution was added to the wells and incubated for one hour at room temperature.  
Following the incubation, the wells were washed two times with 1X TBST and blotted on 
a paper towel to remove excess liquid. 
 During the incubation with the blocking solution, the Ago2/Let-7a complex 
reaction was set up and carried out.  To a nuclease free 0.2 mL PCR tube 2 µL of 
recombinant human Ago2 was added at a concentration of 10 ng/µL, 7.5 µL of TM 
buffer (333 mM KCl, 5 mM MgCl2, 1.67 mM DTT), 2 µL of phosphorylated Let-7a 
miRNA, and 8.5 µL of nuclease free water for a total volume of 20 µL.  Another reaction 
tube was set up with the same reagents but without recombinant Ago2 protein and used 
as a control.  The tubes were closed and incubated for 30 minutes at 30 °C using a 
thermocycler. 
 Following the incubation 5 µL of XRN-1, the equivalent of 5 units, was added to 
each reaction tube.  The tubes were closed and allowed to incubate for an additional 30 
minutes at 37 °C in the thermocycler in order to allow digestion of the free Let-7a.  
Following the incubation, 25 µL of 1% diluent was added to the reaction tubes to bring 
the final volume to 50 µL.  The entire contents of each reaction tube were then 
transferred to the antibody coated microtiter wells. 
 After the reaction mix was added to the wells, the plate was incubated for one 
hour at room temperature while gently shaking on a plate shaker.  Following the 
incubation, the plate was washed five times with 1X TBST and blotted on a paper towel 
to remove excess liquid.  To each sample well, 50 µL of Tris-EDTA buffer was added 
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and the plate was placed in an incubator set at 65 °C for 15 minutes to allow denaturation 
of the Ago2/Let-7a complex.  Following the incubation, the contents of each well was 
quickly transferred to individual nuclease free microfuge tubes using a microtiter pipette.  
Each sample was then reverse transcribed using the Qiagen miScript Reverse 
Transcription Kit.  For each reverse transcription reaction, 2 µL of each sample was used 
along with 4 µL of the 5X miScript HiSpec Buffer, 2 µL of the 10X nucleics mix, 2 µL 
of the miScript reverse transcriptase mix, and RNase-free water for a final volume of 20 
µL.  As a positive control 3.2 µM Let-7a miRNA was used, with 3.2 µM corresponding 
to the total amount of Let-7a miRNA present in the reaction.  The reverse transcription 
reactions were incubated for 60 minutes at 37 °C followed by a five minute incubation at 
95 °C to inactivate the reverse transcriptase. 
 After completion of the reverse transcription reaction, the cDNA products were 
diluted according to the kit protocol by addition of at least 200 µL of nuclease-free water.  
The diluted cDNA products were then used in the real-time PCR reaction.  Nuclease-free 
water was used as a PCR negative.  The Qiagen miScript SYBR Green PCR Kit was used 
to perform the real-time PCR.  For the PCR setup, white 0.2 mL PCR strip tubes were 
used with clear strip caps.  To each tube, 10 µL of 2X QuantiTect SYBR Green PCR 
Master Mix, 2 µL of 10X miScript Universal Primer, 2 µL of the 10X miScript Primer 
Assay (Let-7a forward primer), 2 µL of the diluted cDNA product, and RNase-free water 
for a total volume of 20 µL.  The reaction tubes were then mixed and briefly centrifuged.  
The PCR cycle consisted of an initial incubation step of 15 minutes at 95 °C to activate 
the HotStarTaq DNA polymerase.  The cycle was then 15 seconds at 94 °C to allow 
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denaturation, 30 seconds at 55 °C for annealing, and 30 seconds at 70 °C to allow 
extension.  The complete PCR ran for 40 cycles. 
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Figure 18.  Real-Time PCR Amplification Plot from Let-7a Detection Assay 
 
 
Legend 
Red = PCR Negative Control 
Green = Positive Control 
Blue = Complex Reaction w/ Ago2, coated well 
Yellow = Complex Reaction no Ago2, coated well 
Magenta = Complex Reaction w/ Ago2, uncoated well 
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The results from our first attempt at detecting the Ago2 associated Let-7a yielded 
unexpected results.  However, these results further support data that was observed in 
earlier stages of our study.  From the observed data, all reactions that contained Ago2 
failed to produce an amplified signal for the PCR reaction within 40 cycles.  If you will 
recall from the experimental procedure, the diluent used prior to adding the complex 
reaction to the coated wells was 1% blocking solution.  The decision to use the blocking 
solution as the diluent was made because of the need to block non-specific binding 
between the free Let-7a and the adsorbed antibodies and well surfaces.  Also, the lack of 
a signal from reactions that contained Ago2 would further support the low binding 
affinity of the antibody for the recombinant Ago2 protein when adsorbed on a solid 
phase. 
In order to determine whether our hypothesis was correct, we repeated the 
experiment using 1X PBS as a diluent instead of 1% blocking solution.  By using a 
diluent that did not possess excess proteins, we predicted that the probability of the 
antibody binding the protein complex would be increased.  However, in not using the 
blocking solution as a diluent, we risk further increasing the background of the assay.  
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Figure 19.  Real-Time PCR Amplification Plot from Let-7a Detection Assay Using 
1X PBS as Diluent 
 
 
Legend 
Red = PCR Negative Control 
Green = PCR Positive Control 
Yellow = Complex Reaction w/ Ago2, coated well 
Blue = Complex Reaction no Ago2, coated well  
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 As seen in figure 19 above, the use of 1X PBS as a diluent for the complex 
reaction mix as opposed to using 1% blocking solution resulted in a generated signal 
from the PCR reaction.  We observed amplification from the wells containing the 
Ago2/Let-7a complex.  However, as expected, the high background signal was generated 
as well due to the strong affinity between the polyclonal antibody and miRNA Let-7a.  In 
order for the detectability of the complex to increase it is necessary that the resultant 
background noise be reduced. 
 In earlier experiments we attempted to preemptively reduce the background noise 
produced by the affinity of the polyclonal antibody to the miRNA by using an 
exoribonuclease to digest the free miRNA that existed in the reaction.  This however 
proved to be not as effective as we had hoped and is observable in the results obtained in 
this previous experiment.  As you may recall, the ratio of Ago2 to Let-7a in our complex 
reaction is 1:4 with the purpose ensuring that every Ago2 protein in the reaction has 
bound a miRNA.  Due to the affinity of the antibody for the miRNA, we have 
inadvertently pushed the assay background noise to higher levels.  As is often the case in 
scientific studies and experimental design, compromises have to be made as the data sees 
fit.  We moved forward in our study with a new mind set, that being a modification of the 
Ago2 and Let-7a ratios for the complex reaction.  We decided to invert the ratio for the 
complex reaction and used 4:1 Ago2 to Let-7a with the hope that it would help eliminate 
the problem of the background noise from the free Let-7a. 
 For our next experiment, we not only inverted the ratios for the reaction we also 
used lower molar amounts of Ago2 and Let-7a.  As with the past experiment the two 
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wells of a polystyrene microtiter plate were coated by adding 50 µL of the polyclonal 
antibody at a concentration of 5 µg/mL and allowed to incubate overnight at room 
temperature.  50 µL of 1X PBS was used for the uncoated well. Following the incubation, 
the wells were washed two times with 1X TBST and gently blotted on a paper towel to 
remove excess liquid.  To each well, 200 µL of 1% blocking solution was added and 
allowed to incubate for one hour at room temperature.  While the incubation with the 
blocking solution was going on the Ago2/Let-7a complex reaction was carried out. 
 Three clean, nuclease free, 0.2 mL microtubes were used for the complex 
reactions. In the first tube, 2 µL of [10 ng/µL] Ago2, 7.5 µL of TM buffer (3.33 mM 
ATP, 333 mM KCl, 5 mM MgCl2, 1.67 mM DTT), 2 µL of [25 nM] phosphorylated Let-
7a, and nuclease free water were added for a total reaction volume of 20 µL.  To the 
second tube, the same reagents were added in the same amounts but no Let-7a was added 
to this reaction, only Ago2.  The reaction tubes were then closed and incubated for 30 
minutes at 30 °C using a PCR thermocycler. 
 The timing for the microtiter plate incubation and reaction incubations were 
staggered.  Prior to the completion of the complex reaction incubation, the wells of the 
microtiter plate were washed two times with 1X TBST and gently blotted on a paper 
towel to remove excess liquid.  To each well, 45 µL of 1X PBS was then added.   Then, 
to the first coated well, 5 µL of the complex reaction was added.  To the other coated 
well, 5 µL of the reaction that lacked Let-7a was added, and to the uncoated well 5 µL of 
the complex reaction was added.  The plate was then sealed and allowed to incubate for 
one hour while shaking. 
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 Following the incubation, the plate wells were washed three times with 1X TBST 
and gently blotted on a paper towel to remove excess liquid.  To each well, 50 µL of TE 
(Tris-EDTA) buffer was added and the plate was allowed to incubate for 15 minutes at 65 
°C to denature that protein content of the well and allow elution of the Let-7a.  The liquid 
was then removed from each well and respectively transferred to a labelled, clean, 
microtube.  2 µL of each elution sample was then used for 10 µL reverse transcription 
reactions according to the protocol for the Qiagen miScript Reverse Transcription Kit.  
Following the reverse transcription reaction, 5 µL of undiluted cDNA was used in the 20 
µL real-time PCR reaction according to the protocol for the Qiagen miScript SYBR 
Green PCR Kit. 
  
  
54 
 
Figure 20.  Real-Time PCR Amplification Plot for the Modified Let-7a Detection 
Assay 
 
 
Legend 
Red = no antibody coated, Ago2/Let-7a complex 
Green = polyclonal antibody coated, Ago2/Let-7a complex 
Blue = polyclonal antibody coated, complex reaction mix with Ago2 only, no Let-7a 
 
 
From figure 20, a signal is observed from the sample eluted from the coated well 
incubated with the Ago2/Let-7a complex but not from the well that is uncoated but 
incubated with the Ago2/Let-7a complex.  This is most certainly a positive development 
in our study.  The data demonstrates the necessity of the antibody and its ability to isolate 
the active complex from a sample.  The question now lies with the position of the 
background noise for the assay.  The current experiment supports the use of the antibody 
as a viable means of isolation but we now need to compare the amount of complex 
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associated isolated from the sample with the amount of background noise due to the 
attraction between the miRNA and the antibody. 
 Therefore, the previous experiment was repeated in the same manner but with the 
addition of a few other controls.  In the repeat of the experiment, we coated three wells 
with the polyclonal antibody, and left one uncoated.  One of the coated wells, and the 
uncoated well were incubated with the Ago2/Let-7a complex reaction.  The remaining 
coated well was incubated with the Ago2/Let-7a complex reaction but the Ago2 was 
excluded from the reaction.  PCR controls containing 0.5 fmol and 0.05 fmol Let-7a were 
used. These controls were to correspond to the estimated amount of free Let-7a remaining 
after the dilution of the complex reaction mix and to estimated removal of free Let-7a 
during the washing steps.  All steps of the experiment were the same as in the previous 
experiment. 
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Figure 21.  Real-Time PCR Amplification Plot for the Detection of Ago2 Associated 
Let-7a 
 
 
 
Legend 
Red = PCR positive control (0.5 fmol Let-7a) 
Green = PCR control (0.05 fmol Let-7a) 
Dark Blue = No Coating, with Ago2/Let-7a Complex 
Gold = Coated well, with Ago2/Let-7a Complex 
Yellow = Coated well, with Ago2/Let-7a rxn mix with no Ago2 
 
 
Results of Study 
 
As can be seen from the amplification plot in figure 21, there is a clear distinction 
between the PCR amplification signal from the coated well incubated with the Ago2/Let-
7a and the coated well incubated with just Let-7a.  The plot shows that the well incubated 
with Let-7a only contained a higher number of copies and thus became detectable at a 
lower cycle number, however this outcome is not surprising.  Given the size of the 
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miRNA-Ago2 complex, compared to the free miRNA, we would expect that the free 
miRNA would diffuse to the well surface faster than the complex and block some of the 
available binding sites.  As a result, we would expect the shift in the amplification signal 
for the free miRNA when the miRNA-Ago2 complex is not present in the sample. This 
difference in the two amplification signals shows proof of concept that isolation and 
quantitation of Ago2 associated miRNAs can be achieved using this analytical method.  
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CHAPTER V 
CONCLUSION AND FUTURE WORK 
 
Conclusion 
 The role of miRNA is translational inhibition has been widely studied and it along 
with its binding partner Argonaute 2 protein play a key role in the functionality of the 
RNA-Induced Silencing Complex (RISC).  Conventional methods for studying the RISC 
involve molecular techniques that rely on the total extraction of the cellular RNA from 
the lysate.  However, this method of extracting all of the cellular RNA for analysis does 
not take into account the partnership with the Ago2 for functionality in the matter of 
translational inhibition. 
 In this study we investigated a novel solution to this problem.  We utilized an 
antibody raised against the Ago2 protein as a tool that we could use to isolate the 
functional miRNA from a sample by targeting the miRNA-Ago2 complex.  While there is 
still work to be done, preliminary results show promise.  Although the affinity of our 
selected antibody against Ago2 was not optimal, we were able to demonstrate the 
presence of Ago2 associated miRNAs and distinguish the Ago2 associated miRNA from 
the non-Ago2 associated miRNA using real-time PCR. 
 There is great potential in the optimization of the method we have investigated.  
Most significantly, our investigation provides the foundation for development of an 
analytical method that could detect the functional miRNA directly from samples such as 
  
59 
 
blood.  This could potentially lead to new breakthroughs in how the RISC and the 
regulation of translational inhibition are studied. 
 
Future Work 
 
 In our future work, we seek to investigate the use of different antibodies to go 
after the Ago2 component of the miRNA-Ago2 complex.  The use of a different antibody 
could alleviate the issues we encountered by offering a higher binding affinity and 
possibly a lower affinity for the free miRNA.  However, each is a case by case issue and 
further optimization will need to be performed with the new antibody, from the 
parameters we have already established.  After successfully completing the optimization 
of the assay, we then will seek to quantitate the active miRNA using qRT-PCR.  The last 
phase will involve quantitation of the active miRNA from biological samples.  
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